The Ophthalmic Drugs market is growing due to increase in prevalence of eye disorders and the use of combination therapies. Combination therapies have various advantages over traditional medication such as improved patient compliance and efficacy.The market is segmented into Dry eye drugs, Retinal drugs, Anti-inflammatory/allergy/infective drugs, Anti-glaucoma drugs. Glaucoma has the largest market share in the ophthalmic drugs market.
Ophthalmic drugs are the drugs that are used for the treatment of eye diseases and disorders. The Ophthalmic Drugs market is growing due to increase in prevalence of eye disorders and the use of combination therapies. Combination therapies have various advantages over traditional medication such as improved patient compliance and efficacy.
The drivers that support the growth of ophthalmic drug market are aging population, changing lifestyle, technological changes, and increase in healthcare spending. Lack of awareness among people regarding eye diseases and disorders, absence of health insurance in developing countries are some of the challenges faced by the ophthalmic drugs market.
Ophthalmic drug Market analysis by Treatment:
The market is segmented into Dry eye drugs, Retinal drugs, Anti-inflammatory/allergy/infective drugs, Anti-glaucoma drugs. Glaucoma has the largest market share in the ophthalmic drugs market.
Ophthalmic drug Market analysis by Type
Ophthalmic drug type market is segmented into Prescription drugs and OTC drugs. OTC drugs for ocular allergy and dry eye is rapidly growing.
Ophthalmic drug Market analysis by geography
Geographically, ophthalmic drug market is segmented into North America (US), Europe (Germany, UK, and France), Asia Pacific (Japan, India, and China), and LAMEA. North America has the largest ophthalmic drugs market. Asia is the fastest growing ophthalmic drugs market.
Key players in the market focus on product launch, research & new product development, and mergers & acquisition. Product launch, with new combination therapies is the most important strategy adopted by major players in market. Novartis (ALCON), Allergan, Santen, Pfizer, Merck and Roche are the major players in the global ophthalmic drugs market. ALCON launched ILEVRO Suspension used to reduce pain and inflammation resulting from cataract surgery.
High Level Analysis
Porter’s five forces model reveals that bargaining power of supplier is less due to low switching cost and bargaining power of buyers is high due to availability of substitute products. Threat of substitute is high due to similarity in therapeutic functioning. Business strategies adopted by key players are analyzed. SWOT analysis helps in understanding the internal and external factors required for strategic business planning.
This report analyses the factors that are driving and limiting the growth of the market estimations are done according to the market trends for the period 2013-2018Analysis of key strategies adopted by market players would assist in providing in-depth understanding of the market intelligence. In-depth analysis of segments such as targeted drug, type, and geography provides insights that would allow companies to gain competitive edge Emphasis is laid on key factors affecting the growth of global ophthalmic drugs market. These factors are critically analyzed to reveal the most influencing factors in ophthalmic drugs market.
The Ophthalmic drugs market is segmented based on Targeted drugs, Types and geography.
MARKET BY TARGETED DRUGS
- Dry eye Drugs
- Retinal Drugs
- Anti-inflammatory/Allergy/Infective Drugs
- Anti-Glaucoma Drugs
MARKET BY TYPE
- Prescription Drugs
- OTC Drugs
MARKET BY GEOGRAPHY